Cardiovascular Biology of Microsomal Prostaglandin E Synthase-1

Trends in Cardiovascular Medicine

Volumn 20, Issue 6, 2010, Pages 189-195

  Wang, Miao ^a   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; CYCLOOXYGENASE 2; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E SYNTHASE 1;

BLOOD PRESSURE; CAROTID ARTERY; HEART FUNCTION; HYPERLIPIDEMIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INTRAMOLECULAR OXIDOREDUCTASES; NEOINTIMA;

EID: 83055179062     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2011.04.002     Document Type: Review

References (65)

1. 2 induces heme oxygenase-1 gene expression in a reactive oxygen species-dependent manner in human lymphocytes. J Biol Chem 2004, 279:21929-21937.
2. Babaev V.R., Chew J.D., Ding L., et al. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. Cell Metab 2008, 8:492-501.
3. Brenneis C., Coste O., Altenrath K., et al. Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem 2011, 286:2331-2342.
4. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
5. Chan C.C., Reid C.M., Aw T.J., et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo?. An updated meta-analysis. J Hypertens 2009, 27:2332-2341.
6. Chen M., Boilard E., Nigrovic P.A., et al. Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis. Arthritis Rheum 2008, 58:1354-1365.
7. 2. Science 2002, 296:539-541.
8. Cheng Y., Wang M., Yu Y., et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 2006, 116:1391-1399.
9. 2 production in the rat adjuvant-induced arthritis model. J Immunol 2003, 170:4738-4744.
10. 2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 2008, 117:1701-1710.
11. Dowd N.P., Scully M., Adderley S.R., et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 2001, 108:585-590.
12. Egan K.M., Lawson J.A., Fries S., et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004, 306:1954-1957.
13. Egan K.M., Wang M., Fries S., et al. Cyclooxygenases, thromboxane, and atherosclerosis: Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005, 111:334-342.
14. Engblom D., Saha S., Engström S., et al. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Net Neurosci 2003, 6:1137-1138.
15. 2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001, 107:603-610.
16. Forsberg L., Leeb L., Thoren S., et al. Human glutathione dependent prostaglandin E synthase: Gene structure and regulation. FEBS Lett 2000, 471:78-82.
17. Francois H., Facemire C., Kumar A., et al. Role of microsomal prostaglandin E synthase 1 in the kidney. J Am Soc Nephrol 2007, 18:1466-1475.
18. Garcia Rodriguez L.A., Tacconelli S., Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008, 52:1628-1636.
19. Golledge J., Muller J., Daugherty A., Norman P. Abdominal aortic aneurysm: Pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006, 26:2605-2613.
20. Grosser T., Fries S., FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006, 116:4-15.
21. Grosser T., Yu Y., FitzGerald G.A. Emotion recollected in tranquility: Lessons learned from the COX-2 saga. Annu Rev Med 2010, 61:17-33.
22. Hanaka H., Pawelzik S.C., Johnsen J.I., et al. Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc Natl Acad Sci USA 2009, 106:18757-18762.
23. Harding P., Yang X.P., He Q., Lapointe M.C. Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion. Am J Physiol Heart Circ Physiol 2011, 300:H1053-H1056.
24. Jakobsson P.J., Thoren S., Morgenstern R., Samuelsson B. Identification of human prostaglandin E synthase: A microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999, 96:7220-7225.
25. 2. Proc Natl Acad Sci USA 2008, 105:11110-11115.
26. Jia Z., Zhang A., Zhang H., et al. Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. Circ Res 2006, 99:1243-1251.
27. Kamei D., Yamakawa K., Takegoshi Y., et al. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1. J Biol Chem 2004, 279:33684-33695.
28. 2 via the PI3 kinase and AKT pathway. J Biol Chem 2007, 282:5356-5366.
29. 2 as a therapeutic target for multiple sclerosis. Proc Natl Acad Sci USA 2009, 106:21807-21812.
30. King V.L., Trivedi D.B., Gitlin J.M., Loftin C.D. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 2006, 26:1137-1143.
31. Kobayashi T., Tahara Y., Matsumoto M., et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004, 114:784-794.
32. Koo B.K., Kim Y.S., Park K.W., et al. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): An open-label randomised controlled study. Lancet 2007, 370:567-574.
33. Linton M.F., Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 2004, 4:116-123.
34. Murakami M., Kudo I. Prostaglandin E synthase: A novel drug target for inflammation and cancer. Curr Pharm Des 2006, 12:943-954.
35. Nakanishi M., Montrose D.C., Clark P., et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 2008, 68:3251-3259.
36. Pawelzik S.C., Uda N.R., Spahiu L., et al. Identification of key residues determining species differences in inhibitor binding of microsomal prostaglandin E synthase-1. J Biol Chem 2010, 285:29254-29261.
37. Pini B., Grosser T., Lawson J.A., et al. Prostaglandin E synthases in zebrafish. Arterioscler Thromb Vasc Biol 2005, 25:315-320.
38. Qi Z., Hao C.M., Langenbach R.I., et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 2002, 110:61-69.
39. Radmark O., Samuelsson B. Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: Potential drug targets in cancer. J Intern Med 2010, 268:5-14.
40. Rudic R.D., Brinster D., Cheng Y., et al. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 2005, 96:1240-1247.
41. Sakalihasan N., Delvenne P., Nusgens B.V., et al. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg 1996, 24:127-133.
42. Sakalihasan N., Limet R., Defawe O.D. Abdominal aortic aneurysm. Lancet 2005, 365:1577-1589.
43. Samuelsson B., Morgenstern R., Jakobsson P.J. Membrane prostaglandin E synthase-1: A novel therapeutic target. Pharmacol Rev 2007, 59:207-224.
44. Schneider A., Zhang Y., Zhang M., et al. Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney. Kidney Int 2004, 65:1205-1213.
45. Scholich K., Geisslinger G. Is mPGES-1 a promising target for pain therapy?. Trends Pharmacol Sci 2006, 27:399-401.
46. + channels via the EP3 receptor. Am J Physiol Heart Circ Physiol 2005, 288:H2093-H2101.
47. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080.
48. Solomon S.D., Wittes J., Finn P.V., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis. Circulation 2008, 117:2104-2113.
49. Tang E.H., Shimizu K., Christen T., et al. Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions. Cardiovasc Res 2011, 89:234-243.
50. 2 biosynthesis. J Biol Chem 2000, 275:32775-32782.
51. Thomas M., Gavrila D., McCormick M.L., et al. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation 2006, 114:404-413.
52. Thoren S., Weinander R., Saha S., et al. Human microsomal prostaglandin E synthase-1: Purification, functional characterization, and projection structure determination. J Biol Chem 2003, 278:22199-22209.
53. Trebino C.E., Stock J.L., Gibbons C.P., et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 2003, 100:9044-9049.
54. 2 synthesis in abdominal aortic aneurysms: Implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999, 100:48-54.
55. Wang D., Patel V.V., Ricciotti E., et al. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci USA 2009, 106:7548-7552.
56. Wang K., Tarakji K., Zhou Z., et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol 2005, 45:61-67.
57. Wang M., Cooper P.R., Jiang M., et al. Deletion of microsomal prostaglandin E synthase-1 does not alter ozone-induced airway hyper-responsiveness. J Pharmacol Exp Ther 2010, 334:63-68.
58. 2 synthase-1 modulates the response to vascular injury. Circulation 2011, 123:631-639.
59. Wang M., Lee E., Song W., et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 2008, 117:1302-1309.
60. Wu D., Mennerich D., Arndt K., et al. Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice. Prostaglandins Other Lipid Mediat 2009, 90:21-25.
61. Wu D., Mennerich D., Arndt K., et al. The effects of microsomal prostaglandin E synthase-1 deletion in acute cardiac ischemia in mice. Prostaglandins Leukot Essent Fatty Acids 2009, 81:31-33.
62. Xing L., Kurumbail R.G., Frazier R.B., et al. Homo-timeric structural model of human microsomal prostaglandin E synthase-1 and characterization of its substrate/inhibitor binding interactions. J Comput Aided Mol Des 2009, 23:13-24.
63. 1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther 2008, 326:754-763.
64. Yang H.M., Kim H.S., Park K.W., et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 2004, 110:301-308.
65. Yang T., Huang Y.G., Ye W., et al. Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice. Am J Physiol Renal Physiol 2005, 288:F1125-F1132.